Preclinical Drug Discovery

The Need for a New Model

Drugs express activity in complexes that trigger cascades of responses in living cells.  The whole arsenal of the intracellular reactions is a subject of extensive investigations in many post-genomics fields of life sciences. And it applies to both types of drugs, small molecules, and biologics. The immunogenicity of biopharmaceuticals is a result of many factors. Most of them are product or process-related. Therefore, the success in the selection of small-molecule drug candidates in the preclinical drug discovery process requires a fundamental knowledge of receptor folding and properties. 

BioGlobaX Inc. provides scientific expertise and consulting services to preclinical drug discovery companies. We apply cost-effective, multidisciplinary approaches, coupled with bioinformatics tools and high-throughput, state-of-the-art technologies (read our article). It helps our clients to streamline the process for the production of viable drugs with benefits to: 

  • Achieve consistent results
  • Minimize variables, risk, time, and costs
  • Successfully manage each step and the entire R&D pathway
  • Maximize accomplishments, in vivo efficacy, and proof of concepts. 

Our commitment is to fill the gap between university research and the pharmaceutical industry.  Along with governmental support, this will promote the drug discovery efforts to replace inefficient old models with new and proven alternatives. The prior focus of all sizes of companies was on pharmacology and toxicology for the successful output of drug candidates for clinical trials. It is now apparent that more effort on a molecular level at the earliest stage of the drug discovery process is crucial.

Paradigm Shift

The traditional preclinical R&D pathway is sequential, long, and expensive due to the complexity of the proteins either as drugs or as drug receptors. One of the main tasks for researchers is to reduce variables during bioanalytical assays. Recently, expression, biophysical, and pharmacological screening technologies have been developed to optimize some of the steps and to search for factors that may improve protein yield and activity.

Drug Discovery Pathway

Multidisciplinary approaches allow comprehensive analysis and rapid decline of variables and repetitions. It is essential to apply them in parallel at the very beginning of the R&D process. The balance between internal and external research is crucial for a successful outcome. This balance has an impact on the communication efficiency between researchers and service providers to avoid misinterpretation of the results.

Our extensive research experience has allowed us to develop cost-effective, innovative, and practical solutions from the initial steps of the R&D process. We complement a large variety of techniques developed in universities that provide a robust pool of information. Our Design of Experiments (DoE) approaches allow for a deeper understanding of the complexity of proteins and how to manage the process more efficiently.  

Drug discovery comparative pathways
Sequential VS DoE in Preclinical R&D Drug Discovery